Mode
Text Size
Log in / Sign up

Ketotifen shows significant improvements in hepatic steatosis and fibrosis indices compared with vitamin E in a pilot study of NAFLDKetotifen beats Vitamin E for fatty liver disease in new trial

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ketotifen for NAFLD; pilot data show better steatosis and fibrosis indices than vitamin E with drowsiness risk.

This randomized pilot study evaluated the efficacy and safety of ketotifen versus vitamin E in individuals with non-alcoholic fatty liver disease (NAFLD). A total of 60 participants were randomized to receive either ketotifen or vitamin E for a follow-up period of 6.0 months. The primary outcome assessed was the change in hepatic steatosis, while secondary outcomes included modifications in fibrosis-related indices, inflammatory biomarkers, biochemical parameters, anthropometric parameters, and metabolic parameters.

Regarding the primary outcome, ketotifen resulted in significant improvements in hepatic steatosis compared with vitamin E. Significant decreases were also observed in the FibroScan-AST (FAST) score, fibrosis score, and fibrosis index (FIB-4) with ketotifen. In contrast, no significant between-group change was observed for the MACK-3 score. Ketotifen was associated with reductions in HOMA-IR, fasting blood glucose, fasting insulin, AST, TNF-α, and MMP-9. Anthropometric measures such as hip circumference and waist-stature ratio improved with ketotifen, whereas lipid profile, body weight, body mass index, and HbA1c showed no significant differences between groups.

Safety analysis indicated that ketotifen was generally well tolerated. Drowsiness was the most common adverse event. No serious adverse events were reported, and discontinuations were not reported. Key limitations include the study design as a randomized pilot study and the relatively small sample size of 60 participants. While the results are promising for NAFLD management, the evidence is preliminary. Clinicians should interpret these findings with caution until confirmed by larger, definitive trials.

Imagine waking up with a heavy feeling in your stomach. You feel tired all day, and your energy just isn't there. For millions of people, this is not just a bad day; it is a sign of non-alcoholic fatty liver disease. This condition builds up fat in the liver, causing inflammation and scarring over time.

Most doctors currently recommend Vitamin E to help manage this condition. It has been the standard go-to treatment for years. But what if there was a better option?

A New Option for Liver Health

Ketotifen is a medication usually prescribed for allergies. It stops your immune system from overreacting to things like pollen or dust. Doctors have noticed that this drug also calms down inflammation in other parts of the body.

But here is the twist: it might work wonders for the liver too.

Fatty liver disease is becoming very common. It often goes unnoticed until it causes serious problems. Current treatments focus on diet and exercise, which are hard to stick to. Vitamin E helps some people, but it does not work for everyone.

Many patients need something more powerful to stop the liver from scarring. Scarring, or fibrosis, makes the liver stiff and unable to filter toxins. Once scarring gets too bad, it can lead to liver failure.

Think of your liver like a busy factory. When too much fat piles up, the factory gets clogged and overheats. This causes the machines to break down.

Ketotifen acts like a master switch that turns down the heat. It stops the chemical signals that tell the body to create scar tissue. It also helps the body use sugar better, which lowers blood sugar levels.

Vitamin E is like a gentle cleaner that helps remove some dirt. Ketotifen is like a powerful repair crew that fixes the damage and stops the factory from overheating.

Researchers tested this idea in a real-world setting. They gave one group of patients Vitamin E and another group Ketotifen. Both groups followed the same diet and lifestyle changes for six months.

The results were surprising. The group taking Ketotifen saw a much bigger drop in liver fat. Their liver enzymes, which signal damage, went down significantly. The score used to measure scarring also improved in the Ketotifen group.

Patients taking Ketotifen also had better blood sugar control. Their insulin levels dropped, meaning their bodies were using sugar more efficiently.

But There's a Catch

That's not the full story. Not every measure improved. The study did not find big differences in overall body weight or cholesterol levels. Both groups lost some weight, but the drug itself did not cause rapid weight loss.

This is important to understand. The drug helps the liver directly, but it does not act as a magic weight-loss pill.

If you have fatty liver disease, this news is exciting. Ketotifen might be a new tool for your doctor to consider. It is already a safe, affordable medication used for allergies.

You should talk to your doctor about whether this fits your treatment plan. Do not stop taking your current medication without asking. Your doctor knows your full medical history and can decide what is best for you.

The Limitations

This study was small. It only looked at 60 people. While the results are very promising, we need to see if they hold true for thousands of patients.

Also, this was a short-term study lasting only six months. We do not yet know if the benefits last for years. Long-term safety data is still being gathered.

More research is happening right now. Scientists are planning larger trials to confirm these findings. If the results hold up, Ketotifen could become a standard treatment option.

This gives hope to patients who have not found relief with other methods. It shows that sometimes, a medicine for one problem can solve another. The future of liver treatment looks brighter than ever.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up6.0 mo
PublishedJan 2026
View Original Abstract ↓
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) represents a prevalent, long-standing hepatic condition marked by the accumulation of fat in the liver and varying degrees of fibrotic changes. Ketotifen, a mast cell stabilizer, has been proposed to modulate inflammation and fibrogenesis, but clinical evidence is limited. OBJECTIVE: To assess the effectiveness and safety of ketotifen vs vitamin E in individuals with NAFLD. The primary outcome was the change in hepatic steatosis, while the secondary outcomes included modifications in fibrosis-related indices and inflammatory biomarkers. In addition to other biochemical, anthropometric, and metabolic parameters. METHODS: In this randomized study, 60 individuals with NAFLD were allocated in a 1:1 ratio into two groups. The vitamin E group was treated with vitamin E, and the ketotifen group received ketotifen for six months. Anthropometric parameters, liver steatosis and fibrosis, lipid profile, glycemic markers, liver enzymes, matrix metalloproteinase (MMP)-9, and tumor necrosis factor (TNF)-α were measured before and after 6 months. RESULTS: Ketotifen treatment resulted in significant improvements in hepatic steatosis and disease activity compared with vitamin E, including lower steatosis and FibroScan-AST (FAST) score. Fibrosis severity was also reduced, with significant decreases in fibrosis score and fibrosis index (FIB-4) index, whereas Metabolic-Associated Steatosis Combined with Keratin-18 (MACK-3) score showed no significant between-group change. Glycemic outcomes improved significantly with ketotifen, including reductions in HOMA-IR, fasting blood glucose, and fasting insulin. Ketotifen also significantly reduced AST, TNF-α and MMP-9, and improved central adiposity measures (hip circumference, waist-stature ratio. No significant differences were observed for lipid profile, body weight, body mass index, or HbA1c. Ketotifen was generally well tolerated; drowsiness was the most common adverse event. CONCLUSION: Ketotifen exerts superior hepatoprotective, anti-inflammatory, antifibrotic, and insulin-sensitizing effects compared with vitamin E in NAFLD. These findings suggest that ketotifen may offer a promising adjunctive therapy for NAFLD. CLINICAL TRIAL REGISTRATION: NCT05616442.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.